Navigation Links
Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
Date:3/3/2009

ibo for the treatment of adult ALL from the U.S. Food and Drug Administration. Marqibo has also received orphan drug designation from the European Medicines Evaluation Agency in adult ALL.

About Marqibo(R) (vincristine sulfate liposomes injection)

Marqibo is a novel, targeted, Optisomal(TM) formulation of vincristine, a widely-used chemotherapy, which has shown promising anti-cancer activity in patients with ALL, non-Hodgkin's lymphoma, Hodgkin's disease, and melanoma in several clinical trials. Vincristine is approved by the U.S. Food and Drug Administration as a single agent and in combination regimens for the treatment of hematologic malignancies such as lymphomas and leukemias. Vincristine, a microtubule inhibitor, kills cancer cells when they enter a very specific point in the cell cycle, and its efficacy is concentration- and exposure duration-dependent. Marqibo is designed to enhance the penetration and retention of vincristine at sites of active cancer and facilitate dose-intensification compared to standard vincristine formulations. Unlike regular vincristine, Marqibo is dosed based on patient body surface area without the need to limit the dose to avoid early dose-limiting neurotoxicities.

About Hana Biosciences, Inc.

Hana Biosciences, Inc. (Nasdaq: HNAB) is a biopharmaceutical company dedicated to developing new, differentiated cancer therapies designed to improve and enable current standards of care. The Company has two lead product candidates that target large markets and are in pivotal and/or proof-of-concept clinical trials. Marqibo is being developed to treat lymphoid cancers such as ALL and lymphomas. Menadione topical lotion is a first-in-class compound being developed as a prevention and/or treatment of skin toxicity associated with epidermal growth f
'/>"/>

SOURCE Hana Biosciences
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
2. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
3. YM BioSciences Announces Milestone Payment For Approval Of Nimotuzumab In The Philippines And Indonesia
4. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
5. Chipscreen Biosciences and HUYA Bioscience Intl Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
6. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
7. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
8. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
9. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
10. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
11. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014  Chuma Holdings, Inc. (OTCBB:CHUM) ... and turnkey support services for the lawfully organized ... processed and approved the Company,s name and symbol ... Corporation will be known as Chuma Holdings, Inc. ... through a merger with the Company,s wholly-owned subsidiary, ...
(Date:8/29/2014)... 2014 /PRNewswire-iReach/ -- SAM Medical Products Implements Voluntary ... SAM Junctional Tourniquet.  Photo - ... Products announced today that it has begun notifying ... potential issue with a clip used to secure ... of the SAM Junctional Tourniquet (SJT).  The company ...
(Date:8/29/2014)...   Mast Therapeutics, Inc. (NYSE MKT: ... Santosh Vetticaden, Chief Medical Officer and Senior Vice ... reasons, in mid-September.  Edwin L. Parsley , ... which Mast acquired earlier this year, will assume ... Chief Medical Officer.  Dr. Parsley previously was with ...
Breaking Medicine Technology:CannaMed Announces Name Change and Trading Symbol Change 2CannaMed Announces Name Change and Trading Symbol Change 3SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4
... Subtypes of AML, Including Those with Poorest Prognoses , ... Eisai Corporation of North America today announced data from a ... (decitabine for injection) in acute myeloid leukemia (AML), the most ... with AML, who often have limited options due to comorbidities ...
... and AMSTERDAM, December 8 ,Agendia, a world leader ... and the Netherlands Cancer Institute researchers will present,data ... Breast Cancer Symposium,(SABCS) and Agendia will support, with ... Cancer Therapy symposium. The San Antonio,Breast Cancer Symposium, ...
Cached Medicine Technology:Dacogen(R) (decitabine for injection) Data Presented on a Phase II Clinical Trial in Elderly Patients with Acute Myeloid Leukemia (AML) 2Dacogen(R) (decitabine for injection) Data Presented on a Phase II Clinical Trial in Elderly Patients with Acute Myeloid Leukemia (AML) 3Dacogen(R) (decitabine for injection) Data Presented on a Phase II Clinical Trial in Elderly Patients with Acute Myeloid Leukemia (AML) 4Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium 2Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium 3Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium 4
(Date:9/1/2014)... (PRWEB) September 01, 2014 "Women struggle ... These hormonal daily changes begin as early as 15, ... their lives negotiating the ups and downs of hormone ... thin or even healthy sizes seems to rage against ... As a woman in her 40's begin to face ...
(Date:9/1/2014)... Thompson HealthDay Reporter FRIDAY, ... previously given to two American aid workers successfully cured a ... tests, researchers report. The drug, ZMapp, prompted recovery in ... get the medication until five days after infection. ZMapp ... days or even hours away from death, said study senior ...
(Date:9/1/2014)... Monday 1 September 2014: Permanent atrial fibrillation (AF) ... according to research in more than 6 000 patients ... from Belgium. The findings suggest that a simple clinical ... to better estimate stroke risk. , Ischaemic stroke is ... for over a million deaths and many more disabled ...
(Date:9/1/2014)... 2014 The National Association of Hispanic ... Dawn Bazarko, DNP, MPH, RN, and Adriana Perez, PhD, ... Academy of Nursing. They will be inducted with Immediate ... whose induction we reported last May. , Our three ... the 2014 American Academy of Nursing Policy Conference in ...
(Date:9/1/2014)... New York (PRWEB) September 01, 2014 ... store, retrieve, organize and analyze biological and genetic ... of the activity of developing software tools to ... not to be confused with biological computation. While ... better understanding of biology can its related concepts, ...
Breaking Medicine News(10 mins):Health News:Female Hormonal Imbalances - Can’t Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today 2Health News:Female Hormonal Imbalances - Can’t Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today 3Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 2Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 3Health News:Permanent AF doubles risk of stroke compared to paroxysmal AF 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 4Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4
... drug use, delivery made a measurable impact in Planned ... Two changes to the way Planned Parenthood clinics perform ... the rate of serious infections, a new report says. ... the area between the gum and the cheek (buccal ...
... ... essential for embryonic stem cells to maintain their all-purpose, pluripotent state. Exploiting the finding ... a strategy to efficiently reprogram mature cells back into the pluripotent state, an elusive step ... , ...
... In a new letter to the three key leaders shaping ... Ways and Means Chairman Charles Rangel (D-NY), Energy and Commerce ... Miller (D-CA) - the Coalition to Protect Senior Care (CPSC) ... could harm seniors, care, cut thousands of key frontline care ...
... more articulate essays were protected from symptoms , WEDNESDAY, July ... early adulthood were less likely to have Alzheimer,s disease later ... that are hallmarks of the disease. , Also, ... neurons, according to a study appearing in the July 9 ...
... tell you that raising a preschooler is no easy task. ... up a child with autism or a developmental delay. ... about their experiences and found that moms of children with ... than mothers of children with developmental delay. Children,s problem ...
... , CHICAGO, July 8 The ... of its 75 city tour, including the top 10,Hispanic cities, ... benefits. The tour recently cruised through Chicago hosting free,events to ... drink well,with nature,s wellness drink: milk. , ...
Cached Medicine News:Health News:Changes Reduced Infections From Medical Abortion 2Health News:Changes Reduced Infections From Medical Abortion 3Health News:Stem Cells' "Suspended" State Preserved by Key Step, Scientists Report 2Health News:Stem Cells' "Suspended" State Preserved by Key Step, Scientists Report 3Health News:Stem Cells' "Suspended" State Preserved by Key Step, Scientists Report 4Health News:New Letter to Rangel, Waxman, Miller from National Seniors Coalition Outlines Concerns With House Tri-Committee Health Reform Bill 2Health News:New Letter to Rangel, Waxman, Miller from National Seniors Coalition Outlines Concerns With House Tri-Committee Health Reform Bill 3Health News:New Letter to Rangel, Waxman, Miller from National Seniors Coalition Outlines Concerns With House Tri-Committee Health Reform Bill 4Health News:Greater Language Skills in 20s May Guard Against Alzheimer's 2Health News:Greater Language Skills in 20s May Guard Against Alzheimer's 3Health News:Mothers of children with autism have higher parental stress, psychological distress 2Health News:Mothers of children with autism have higher parental stress, psychological distress 3Health News:The Hispanic got milk? Campaign Visits Chicago from July 2 - July 10 2
... pacemaker family offers some ... automatic devices. Featuring the ... advanced technologies ever seen, ... incorporates the exclusive ventricular ...
... The Guidant INSIGNIA ... sophisticated patient-specific, easy-to-use features ... and enhanced patient safety. ... are programmed using the ...
... model 1688 and model 1488 active-fixation leads ... leads, offering the unsurpassed handling advantages, performance, ... line of active-fixation leads. Implantable with a ... of the Tendril SDX lead is designed ...
... FlashLink Wireless is a stand-alone real-time ... provides for user defined set up, ... for temperature and humidity. It offers ... as hospitals, blood banks, laboratories, refrigerators, ...
Medicine Products: